New functional assay for Amyloid lowering drugs

Newsletter # 57



Cellular models

The pathogenic role of amyloid beta (Aβ) in various dementia related disorders such Alzheimer’s diseases (AD) is well accepted. Compelling evidences indicate the extracellular accumulation of Aβ is already present at the asymptomatic (preclinical) stage of AD. Thus, early intervention to prevent Aβ accumulation appear as attractive strategies for AD treatment.


NEUROFIT has developed a functional neuronal assay that accumulates extracellular Aβ. The system is tailored to assess the efficiency of Aβ lowering drugs such as BACE inhibitors. In parallel, the assay provides also information about the potential safety or neurotoxicity of the tested drug.

  • The example below illustrates the inhibition of Aβ production by BMS-299897 (γ-secretase inhibitor) in cultures of hippocampal neurons (Left Panel). The Right panel indicates that BMS-299897 becomes neurotoxic at concentration ≥ 300 nM.


    You may also be interested in

  • *** , statistically significant as compared to the Control condition


    Inhibition of production of Aβ1-42 by BMS-299897 in cultures of hippocampal neurons.

  • ** , statistically significant as compared to the Control condition


    Effect of BMS-299897 on the survival of hippocampal neurons in cultures.


NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us.
On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please sign up on our mailing list:


e-mail :